Abstract
We report the preparation of magnetic mesoporous silica (MMS) nanoparticles with the potential multifunctionality of drug delivery and magnetic hyperthermia. Carbon-encapsulated magnetic colloidal nanoparticles (MCN@C) were used to coat mesoporous silica shells for the formation of the core-shell structured MMS nanoparticles (MCN@C/mSiO2), and the rattle-type structured MMS nanoparticles (MCN/mSiO2) were obtained after the removal of the carbon layers from MCN@C/mSiO2 nanoparticles. The morphology, structure, magnetic hyperthermia ability, drug release behavior, in vitro cytotoxicity and cellular uptake of MMS nanoparticles were investigated. The results revealed that the MCN@C/mSiO2 and MCN/mSiO2 nanoparticles had spherical morphology and average particle sizes of 390 and 320 nm, respectively. The MCN@C/mSiO2 nanoparticles exhibited higher magnetic hyperthermia ability compared to the MCN/mSiO2 nanoparticles, but the MCN/mSiO2 nanoparticles had higher drug loading capacity. Both MCN@C/mSiO2 and MCN/mSiO2 nanoparticles had similar drug release behavior with pH-controlled release and temperature-accelerated release. Furthermore, the MCN@C/mSiO2 and MCN/mSiO2 nanoparticles showed low cytotoxicity and could be internalized into HeLa cells. Therefore, the MCN@C/mSiO2 and MCN/mSiO2 nanoparticles would be promising for the combination of drug delivery and magnetic hyperthermia treatment in cancer therapy.
Highlights
Chemotherapy is often used for cancer therapy, but the side-effect of toxic free anticancer drugs is very serious to the body.[1]
magnetic colloidal nanoparticles (MCN@C) nanoparticles were synthesized by the previously reported method,[31] and the XRD pattern indicated that the MCN@C nanoparticles mainly had magnetite (JCPDS file 19-0629) or maghemite (JCPDS file 39-1346)
For MCN/mSiO2 nanoparticles, several diffraction peaks indexed to hematite (JCPDS file 33-664) were observed on the XRD pattern, except for the peaks for magnetite or maghemite, which suggests that some magnetite or maghemite in MCN@C nanoparticles have converted to hematite in MCN/mSiO2 nanoparticles due to the calcination treatment for the removal of carbon and surfactant
Summary
Chemotherapy is often used for cancer therapy, but the side-effect of toxic free anticancer drugs is very serious to the body.[1]. This method involves raising the temperature to 43–48°C to deactivate cancer cells,[11,12] where the temperature increase (or heat generation) is caused by magnetic nanoparticles (MNPs) due to the hysteresis loss and/or Néel and Brownian relaxations of MNPs under an alternating magnetic field.[10] Heat can increase the efficacy of different chemotherapeutic drugs in the hyperthermia temperature range.[13] On the other hand, studies demonstrated that MNPs-based hyperthermia treatment may induce anticancer immunity, and can be used for controlled drug delivery.[14] The synergistic therapeutic effects may be achieved by the combination of chemotherapy with magnetic hyperthermia.[15,16,17] the critical issue is to prepare a multifunctional platform with the simultaneous controlled anticancer drug release and magnetic hyperthermia ability To solve this critical issue, magnetic mesoporous silica (MMS) nanoparticles are proposed to be a multifunctional platform for drug delivery and magnetic hyperthermia. Magnetic hyperthermia ability, drug release behavior, biocompatibility and cellular uptake of the MCN@C/ mSiO2 and MCN/mSiO2 nanoparticles were investigated
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
